Claims

1. A pharmaceutical composition comprising:

a first spray dried dispersion and a second spray dried dispersion,

wherein the first spray dried dispersion comprises 70 wt% to about 90 wt% of an amorphous form of (*R*)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) and from about 10 wt% to about 30 wt% of a polymer, wherein the polymer comprises hydroxypropyl methylcellulose, and

wherein the second spray dried dispersion comprises an amorphous form of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 2);

wherein the pharmaceutical composition is a tablet which comprises about 25 mg to 125 mg of Compound 1 and about 100 mg to 200 mg of Compound 2.

2. The pharmaceutical composition of claim 1, wherein the second spray dried dispersion further comprises hydroxypropyl methylcellulose acetate succinate (HPMCAS).

3. The pharmaceutical composition of claim 1 or claim 2, wherein the second spray dried dispersion comprises from about 70 wt% to about 90 wt% of Compound 2 and from about 10 wt% to about 30 wt% of the polymer.

4. The pharmaceutical composition of any of claims 1 to 3, wherein the tablet comprises about 100 mg of Compound 1.

5. The pharmaceutical composition of any of claims 1 to 4, wherein the tablet comprises about 150 mg of Compound 2.

6. The pharmaceutical composition of any of claims 1 to 5, wherein the pharmaceutical composition comprises one or more excipients selected from a filler, a disintegrant, a lubricant, or any combination thereof.

7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition comprises a filler in an amount of about 30 wt% to about 50 wt% by weight of the pharmaceutical composition.

8. The pharmaceutical composition of claim 7, wherein the filler comprises microcrystalline cellulose.

9. The pharmaceutical composition of any of claims 6-8, wherein the pharmaceutical composition comprises from about 1 wt% to about 10 wt% of a disintegrant by weight of the pharmaceutical composition.

10. The pharmaceutical composition of claim 9, wherein the disintegrant comprises croscarmellose sodium.

11. The pharmaceutical composition of any of claims 6-10, wherein the pharmaceutical composition comprises about 1 wt% of a lubricant by weight of the pharmaceutical composition.

12. The pharmaceutical composition of claim 11, wherein the lubricant comprises magnesium stearate.

13. The pharmaceutical composition of any of claims 1-12, wherein the tablet comprises from about 100 mg to about 300 mg of a filler.

14. The pharmaceutical composition of any of claims 1-13, wherein the tablet comprises from about 12 mg to about 36 mg of a disintegrant.

15. The pharmaceutical composition of any of claims 1-14, wherein the tablet comprises 5.9 mg of a lubricant.

16. The pharmaceutical composition of any preceding claim, wherein the tablet has the following formulation:

	Ingredient	Amount per tablet (mg)
Intra-granular	The first spray dried dispersion	125
	The second spray dried dispersion	187.5
	Microcrystalline cellulose	131.4
	Croscarmellose Sodium	29.6
	Total	**473.5**
Extra-granular	Microcrystalline cellulose	112.5
	Magnesium Stearate	5.9
	Total	**118.4**
Total uncoated Tablet		**591.9**
Film coat	Opadry	17.7
Total coated Tablet		**609.6**

.

17. A pharmaceutical composition of any preceding claim for use in a method of treating cystic fibrosis in a patient.

18. The pharmaceutical composition for use as in claim 17, wherein the method comprises orally administering the pharmaceutical composition to the patient.

19. The pharmaceutical composition for use as in claim 17 or claim 18, wherein the method comprises administering one tablet once daily.

20. The pharmaceutical composition for use as in any of claims 17-19, wherein the method comprises administering one tablet once daily followed by the administration of 150 mg of Compound 2 once daily.

21. The pharmaceutical composition for use as in any of claims 17-20, wherein the patient is homozygous in the ΔF508 CFTR mutation.

22. The pharmaceutical composition for use as in any of claims 17-20, wherein the patient is heterozygous in the ΔF508 CFTR mutation.